natgillin/translations-raw huggingface dataset:
The nuclear medicine doctor will inform you if you nee2d3 to take any special precautions after receiving the medicine radiolabelled with EndolucinBeta.
Zdravnik nuklearne medicine vas bo obvestil, ali morate po prejemu zdravila, radioaktivno označenega z radionuklidnim predhodnikom EndolucinBeta, upoštevati kakršne koli posebne previdnostne ukrepe.
The nuclear medicine doctor will only give this medicine during pregnancy if a benefit is expected which would outweigh the risks.
Zdravnik nuklearne medicine vam bo to zdravilo med nosečnostjo dal samo, če pričakovane koristi odtehtajo tveganja.
The NULOJIX infusion must be completed within 24 hours of reconstitution of the powder.
Infundiranje zdravila NULOJIX morate dokončati v 24 urah po raztapljanju praška.
The number embossed on one side refers to the strength (mg) of the tablet: “
Številka vtisnjena na eni strani žvečljive tablete se nanaša na jakost (v mg) tablet: "
The number embossed on one side refers to the strength (mg) of the tablets: “
Številka vtisnjena na eni strani žvečljive tablete se nanaša na jakost (v mg) tablet: "
The number needed to treat (NNT) in contacts of true influenza cases was 10 (95 % CI 9 – 12) and was 16 (95 % CI 15 – 19) in the whole population (ITT) regardless of infection status in the index case.
Število bolnikov, ki jih je treba zdraviti (NNT – “number needed to treat”) pri stikih z virusom influence okuženimi bolniki, je bilo 10 (95-% interval zaupanja 9 – 12) in 16 (95-% interval zaupanja 15–19) med vso populacijo (z namenom zdraviti), ne glede na okužbo.
The number needed to treat (NNT) in contacts of true influenza cases was 10 (95 % CI 9 – 12) and was 16 (95 % CI 15 – 19) in the whole population (ITT) regardless of infection status in the index case.
Število bolnikov, ki jih je treba zdraviti (NNT – “number needed to treat”) pri stikih z virusom influence okuženimi bolniki, je bilo 10 (95-% interval zaupanja 9–12) in 16 (95-% interval zaupanja 15–19) med vso populacijo (z namenom zdraviti) ne glede na okužbo.
The number needed to treat (NNT) in contacts of true influenza cases was 10 (95 % CI 9 – 12) and was 16 (95 % CI 15 – 19) in the whole population (ITT) regardless of infection status in the index case.
Število bolnikov, ki jih je treba zdraviti (NNT – “number needed to treat”) pri stikih z virusom influence okuženimi bolniki, je bilo 10 (95-% interval zaupanja 9–12) in 16 (95-% interval zaupanja 15–19) med vso populacijo (z namenom zdraviti), ne glede na okužbo.
The number of all cause hospitalisations in the adalimumab treatment group was 0.18 per patient year vs.
Število hospitalizacij iz vseh razlogov v skupini, zdravljeni z adalimumabom, je bilo 0,18 na bolnikov-let proti 0,26 na bolnikov-let v placebo skupini.
The number of application spots will depend on the body weight of the dog.
Število mest nanosa je odvisno od telesne teže psa.
the number of blood platelets is reduced.
e število trombocitov zmanjša;
The number of breakthrough pain episodes that responded to treatment was also higher among patients who received Instanyl than those who received placebo.
Število epizod prebijajoče bolečine, v katerih je prišlo do odziva na zdravljenje, je bilo prav tako višje pri bolnikih, ki so prejeli zdravilo Instanyl, kot pri tistih, ki so prejeli placebo.
The number of clotting and bleeding problems experienced by the patients fell during the studies, but the benefit of this was not shown convincingly.
Število pojavov strjevanja in krvavitev, ki so jih imeli bolniki, se je med študijami zmanjšalo, vendar korist tega ni bila prikazana prepričljivo.
The number of doses in the display changes to ‘5’.
Število odmerkov na zaslonu se spremeni v »5«.
The number of extra cases of stroke due to use of HRT will increase with age.
Število dodatnih primerov možganske kapi, zaradi uporabe HNZ, se veča s starostjo.
The number of fatal haemorrhagic events was balanced between the treatment arms; however, all of the events in patients treated with Gazyvaro were reported in Cycle 1.
Število krvavitev s smrtnim izidom je bilo med skupinama uravnoteženo, a vsi dogodki med prejemniki zdravila Gazyvaro so se pojavili v 1. ciklusu.
The number of implants per year depends on how much protection from the sun is needed.
Število implantatov na leto je odvisno
The number of infusions you will be given depends on how you respond to treatment and whether you are receiving treatment before surgery (neoadjuvant therapy) or for disease which has spread.
Število infuzij, ki jih boste dobili, je odvisno od tega, kako se boste odzvali na zdravljenje in tega, ali se boste zdravili pred operacijo (neoadjuvantno) ali za razsejano bolezen.
The number of patients experiencing the co-primary endpoint (CV death, MI, stroke or refractory ischaemia) was 1,035 (16.5%) in the clopidogrel-treated group and 1,187 (18.8%) in the placebo- treated group, a 14% relative risk reduction (95% CI of 6%-21%, p=0.0005) for the clopidogrel- treated group.
Število bolnikov s primarnim opazovanim dogodkom (srčno-žilna smrt, MI, kap ali neodzivna ishemijo) je bilo 1.035 (16,5 %) v skupini zdravljeni s klopidogrelom in 1.187 (18,8 %) v skupini s placebom, to je 14 % zmanjšanje relativnega tveganja (95 % IZ od 6 % - 21 %, p=0,0005) za skupino, zdravljeno s klopidogrelom.
The number of patients experiencing the co-primary endpoint (CV death, MI, stroke or refractory ischaemia) was 1,035 (16.5%) in the clopidogrel-treated group and 1,187 (18.8%) in the placebo- treated group, a 14% relative risk reduction (95% CI of 6%-21%, p=0.0005) for the clopidogrel- treated group.
Število bolnikov s primarnim opazovanim dogodkom (srčno-žilna smrt, MI, kap ali neodzivna ishemijo) je bilo 1.035 (16,5%) v skupini zdravljeni s klopidogrelom in 1.187 (18,8%) v skupini s placebom, to je 14% zmanjšanje relativnega tveganja (95% IZ od 6% -21%, p=0,0005) za skupino, zdravljeno s klopidogrelom.
The number of patients experiencing the co-primary endpoint (CV death, MI, stroke or refractory ischaemia) was 1,035 (16.5%) in the clopidogrel-treated group and 1,187 (18.8%) in the placebo- treated group, a 14% relative risk reduction (95% CI of 6%-21%, p=0.0005) for the clopidogrel-treated group.
Število bolnikov s primarnim opazovanim dogodkom (srčno-žilna smrt, MI, kap ali neodzivna ishemijo) je bilo 1.035 (16,5 %) v skupini zdravljeni s klopidogrelom in 1.187 (18,8 %) v skupini s placebom, to je 14 % zmanjšanje relativnega tveganja (95 % IZ od 6 % -21 %, p=0,0005) za skupino, zdravljeno s klopidogrelom.
The number of patients experiencing the co-primary endpoint (CV death, MI, stroke or refractory ischaemia) was 1,035 (16.5%) in the clopidogrel-treated group and 1,187 (18.8%) in the placebo-treated group, a 14% relative risk reduction (95% CI of 6%-21%, p=0.0005) for the clopidogrel-treated group.
Bolnikov s primarnim opazovanim dogodkom (srčno-žilna smrt, MI, možganska kap ali neodzivna ishemija) je bilo v skupini, zdravljeni s klopidogrelom, 1.035 (16,5 %), v placebo skupini pa 1.187 (18,8 %), kar pomeni 14-odstotno zmanjšanje RT (95-odstotni IZ: 6–21 %, p = 0,0005) v skupini, ki se je zdravila s klopidogrelom.
The number of patients experiencing the co-primary endpoint (CV death, MI, stroke or refractory ischaemia) was 1,035 (16.5%) in the clopidogrel-treated group and 1,187 (18.8%) in the placebo-treated group, a 14% relative risk reduction (95% CI of 6%-21%, p=0.0005) for the clopidogrel-treated group.
Število bolnikov s primarnim opazovanim dogodkom (srčno-žilna smrt, MI, kap ali neodzivna ishemijo) je bilo 1.035 (16,5%) v skupini zdravljeni s klopidogrelom in 1.187 (18,8%) v skupini s placebom, to je 14% zmanjšanje relativnega tveganja (95% IZ od 6% -21%, p=0,0005) za skupino, zdravljeno s klopidogrelom.
The number of patients experiencing the co-primary endpoint (CV death, MI, stroke or refractory ischaemia) was 1,035 (16.5%) in the clopidogrel-treated group and 1,187 (18.8%) in the placebo-treated group, a 14% relative risk reduction (95% CI of 6%-21%, p=0.0005) for the clopidogrel-treated group.
Število bolnikov s primarnim opazovanim dogodkom (SŽ smrt, MI, kap ali neodzivna ishemijo) je bilo 1.035 (16,5 %) v skupini zdravljeni s klopidogrelom in 1.187 (18,8 %) v skupini s placebom, to je 14 % zmanjšanje relativnega tveganja (95 % IZ od 6 % -21 %, p=0,0005) za skupino, zdravljeno s klopidogrelom.
The number of patients experiencing the primary endpoint [cardiovascular (CV) death, myocardial infarction (MI), or stroke] was 582 (9.3%) in the clopidogrel-treated group and 719 (11.4%) in the placebo-treated group, a 20% relative risk reduction (95% CI of 10%-28%; p=0.00009) for the clopidogrel-treated group (17% relative risk reduction when patients were treated conservatively, 29% when they underwent percutaneous transluminal coronary angioplasty (PTCA) with or without stent and 10% when they underwent coronary artery bypass graft (CABG)).
Bolnikov s primarnim opazovanim dogodkom (srčno-žilna smrt, MI ali možganska kap) je bilo v skupini, zdravljeni s klopidogrelom, 582 (9,3 %), v placebo skupini pa 719 (11,4 %), kar pomeni 20- odstotno zmanjšanje RT (95-odstotni IZ: 10–28 %; p = 0,00009) v skupini, ki se je zdravila s klopidogrelom (17-odstotno zmanjšanje RT, če so bili bolniki zdravljeni konzervativno, 29-odstotno, če je bila izvedena perkutana transluminalna koronarna angioplastika (PTCA) z žilno opornico ali brez nje, in 10-odstotno, če je bila izvedena premostitvena operacija koronarnih arterij (CABG).
The number of patients experiencing the primary endpoint [cardiovascular (CV) death, myocardial infarction (MI), or stroke] was 582 (9.3%) in the clopidogrel-treated group and 719 (11.4%) in the placebo-treated group, a 20% relative risk reduction (95% CI of 10%-28%; p=0.00009) for the clopidogrel-treated group (17% relative risk reduction when patients were treated conservatively, 29% when they underwent percutaneous transluminal coronary angioplasty (PTCA) with or without stent and 10% when they underwent coronary artery bypass graft (CABG)).
Delež bolnikov s primarnim opazovanim dogodkom [srčno-žilna (SŽ) smrt, miokardni infarkt (MI) ali kap] je bil 582 (9,3%) v skupini, zdravljeni s klopidogrelom, in 719 (11,4%) v skupini, ki je prejemala placebo, to je 20% zmanjšanje relativnega tveganja (95% IZ od 10% - 28%; p=0,00009) v skupini, zdravljeni s klopidogrelom (17% zmanjšanje relativnega tveganja, če so bili bolniki zdravljeni konzervativno, 29% kadar je bila izvedena perkutana transluminalna koronarna angioplastika (PTCA) z ali brez stenta in 10%, če je bila izvedena premostitvena operacija koronarnih arterij (CABG).
The number of patients treated with ZYTIGA by racial group was Caucasian 520 (95.4%), Black 15 (2.8%), Asian 4 (0.7%) and other 6 (1.1%).
Glede na raso je bilo vključenih v zdravljenje z zdravilom Zytiga 520 (95,4%) belcev, 15 (2,8%) črncev, 4 (0,7%) azijcev in 6 (1,1%) bolnikov drugih ras.
The number of patients treated with ZYTIGA by racial group was Caucasian 737 (93.2%), Black 28 (3.5%), Asian 11 (1.4%) and other 14 (1.8%).
Glede na raso je bilo vključenih v zdravljenje z zdravilom Zytiga 737 (93,2%) belcev, 28 (3,5%) črncev, 11(1,4%) azijcev in 14 (1,8%) bolnikov drugih ras.
The number of patients who responded to treatment was also higher in the Instanyl group than in the placebo group.
Tudi število bolnikov, ki so se odzvali na zdravljenje, je bilo večje v skupini, ki je jemala zdravilo Instanyl, kot v skupini, ki je jemala placebo.
The number of patients with arthritis mutilans and predominant spondylitis subtypes was too small to allow meaningful assessment.
Število bolnikov z mutilirajočim artritisom in prevladujočimi podtipi spondilitisa je bilo premajhno za smiselno oceno.
The number of patients with virologic failure and paired genotypes (baseline and failure) were 71, 11, and 4 for rilpivirine and 30, 10, and 2 for efavirenz, for the tenofovir/emtricitabine, zidovudine/lamivudine, and abacavir/lamivudine regimens, respectively.
Število virološko neuspešnih bolnikov in enakim genotipom (ob začetku zdravljenja in ob ugotovitvi neuspešnosti), je bilo v skupini, ki je prejemala rilpivirin 71, 11 in 4 ter 30, 10 in 2 v skupini, ki je prejemala efavirenz za vsako shemo (tenofovir/emtricitabin, zidovudin/lamivudin, abakavir/lamivudin) posebej.
The number of people who had an immune response against the polysaccharides with Nimenrix was similar to the comparator vaccines.
Število oseb, pri katerih se je s cepivom Nimenrix pokazal imunski odziv proti polisaharidom, je bilo podobno kot pri primerjalnih cepivih.
The number of perampanel subjects taking enzyme inducing anti-epileptic medicinal products was small (n = 9).
Število oseb, ki so jemale perampanel in antiepileptična zdravila, ki spodbujajo encime, je bilo majhno (n = 9).
the number of platelets (which help the blood to clot) may fall (thrombocytopenia) a certain type of blood fats (triglycerides) may increase (will show up in blood tests), see section 2 ‘Warnings and precautions’
zmanjša se lahko število trombocitov (ki pomagajo pri strjevanju krvi) (trombocitopenija) povečajo se lahko vrednosti določenih vrst maščob v krvi (trigliceridi) (to pokažejo krvne preiskave), glejte poglavje 2, Opozorila in previdnostni ukrepi
the number of platelets (which help the blood to clot) may fall (thrombocytopenia), a certain type of blood fats (triglycerides) may increase (will show up in blood tests), see section 2 “Warnings and precautions”,
lahko se zmanjša število trombocitov (ki pomagajo pri strjevanju krvi) (trombocitopenija) lahko se zvišajo vrednosti določenih maščob v krvi (trigliceridov) (to pokažejo krvne preiskave), glejte poglavje 2 Opozorila in previdnostni ukrepi
The number of prior lines of therapy ranged from 1 to 9.
Število predhodnih linij zdravljenja je bilo od 1 do 9.
the number of red cells in the blood may fall (anaemia)
zmanjša se lahko število rdečih krvnih celic (anemija)
the number of red cells in the blood may fall (anaemia),
lahko se zmanjša število rdečih krvnih celic (anemija)
The number of scheduled treatment visits after the initial 3 injections, was 13 and 20 for the TE and PRN regimens, respectively.
Pri shemi “Zdravi in podaljšaj” je bilo število dogovorjenih obiskov po začetnih 3 injekcijah 13, pri shemi odmerjanja pro re nata, pa 20.
The number of SREs was also significantly reduced with Ibandronate 6 mg and there was a 40% reduction in the risk of a SRE over placebo (relative risk 0.6, p = 0.003).
Pri bolnikih, zdravljenih s 6 mg ibandronske kisline, je bilo število SRE značilno zmanjšano, tveganje za nastanek SRE pa 40 % manjše (relativno tveganje 0,6, p = 0,003) v primerjavi s placebom.
The number of times you have the drip depends on:
Kako pogosto boste dobivali infuzijo, je odvisno od:
The number of units is shown in the dose window of the pen regardless of strength and no dose conversion should be done when transferring a patient to a new strength.
Število enot je prikazano v okencu za prikaz odmerka na injekcijskem peresniku, ne glede na jakost, in ob prehodu bolnika na novo jakost se ne sme izvajati pretvorbe odmerka.
The number of units of factor IX administered is expressed in International Units (IU), which are related to the current International Standard for factor IX concentrate as approved by the WHO.
Število enot danega faktorja IX izražamo v mednarodnih enotah (i.e.), ki so povezane z veljavnim Mednarodnim standardom za koncentrat faktorja IX, kot ga je odobrila WHO.
The number of units of factor VIII administered is expressed in International Units (IU), which is related to the current WHO standard for factor VIII products.
Število apliciranih enot faktorja VIII je izraženo v mednarodnih enotah (i.e.), ki se nanašajo na veljavni standard SZO za zdravila s faktorem VIII.
The number of units of factor VIII is expressed in International Units (IU), which are related to the current WHO standard for factor VIII products.
Število apliciranih enot faktorja VIII je izraženo v mednarodnih enotah (i.e.), trenutnim standardom Svetovne zdravstvene organizacije za zdravila s faktorjem VIII.
The number of units of FVIII administered is expressed in International Units (IU), which is related to the current WHO standard for FVIII products.
Število danih enot F VIII je izraženo v mednarodnih enotah (i.e.), ki se nanašajo na trenutni standard WHO za zdravila F VIII.
The number of units of FVIII administered is expressed in International Units (IU), which is related to the current WHO standard for FVIII products.
Število danih enot FVIII je izraženo v mednarodnih enotah (i.e.), ki se nanašajo na trenutni standard WHO za zdravila FVIII.
The number of vials of BRINAVESS concentrate required to prepare the appropriate quantity of solution for the treatment of an individual patient will depend on the patient’s weight, and the vial size.
Število vial s koncentratom zdravila BRINAVESS, potrebnih za pripravo ustrezne količine raztopine za zdravljenje posameznega bolnika, je odvisno od mase bolnika in velikosti viale.
The number of vials to be diluted based on the individual patient’s weight and the recommended dose of 2 mg/kg is determined, using the following calculation:
Število vial, ki jih je treba razredčiti, se določi na podlagi bolnikove telesne mase in priporočenega odmerka 2 mg na kg telesne mase z naslednjim izračunom:
The number of vials to be diluted for infusion should be determined based on the patient’s weight and prescribed dose.
Na podlagi bolnikove telesne mase in predpisanega odmerka je treba določiti število vial, ki jih je treba razredčiti za infundiranje.
The number of vials to be diluted for infusion should be determined based on the patient’s weight and prescribed dose.
Na podlagi bolnikove telesne mase in predpisanega odmerka je treba določiti število vial, ki jih želite razredčiti za infundiranje.
The number of vials to be diluted should be determined based on the individual patient’s weight and the recommended dose of 0.5 mg/kg.
Glede na bolnikovo telesno maso in priporočeni odmerek 0,5 mg/ml določite število vial, ki jih morate razredčiti.
The number of vials to be reconstituted is determined based on the individual patient’s weight and the prescribed dose.
Število vial, ki jih je treba rekonstituirati, določite glede na bolnikovo telesno maso in predpisani odmerek.
The number of VTEs per year with low dose CHCs is fewer than the number expected in women during pregnancy or in the postpartum period.
Število VTE na leto je z nizkoodmernimi CHC manjše, kot je pričakovano število VTE pri ženskah med nosečnostjo in v obdobju po porodu.
the number of white blood cells called neutrophils is reduced.
e število belih krvnih celic, imenovanih nevtrofilci, zmanjša;
the number of white blood cells is too low you have a severe liver disease.
imate premajhno število belih krvnih celic, imate hudo bolezen jeter.
the number of white blood cells is too low you have a severe liver disease.
ste alergični (preobčutljivi) na docetaksel ali katerokoli sestavino zdravila Docetaxel Teva Pharma, imate premajhno število belih krvnih celic, imate hudo bolezen jeter.
the number of white blood cells is too low. you have a severe liver disease.
imate premajhno število belih krvnih celic. imate hudo bolezen jeter.
the number of white blood cells is too low. you have a severe liver disease..
imate premajhno število belih krvnih celic. imate hudo bolezen jeter.
the number of your blood cells the amount in your blood of things like sugar, fat or cholesterol.
številu krvnih celic, količinah drugih snovi v krvi, kot so krvni sladkor, maščobe ali holesterol.
the number of your white blood cells is too low (neutrophil counts less than or equal to 1,500 /mm3),
če imate premalo belih krvnih celic (število nevtrofilcev manj kot ali enako 1.500/mm3),
The numbers are to help you prepare and administer your medicine.
Številke so namenjene za pomoč pri pripravi in dajanju zdravila.
The numbers displayed in the Dose Feedback Window help you to:
Številke, prikazane v oknu za prikaz odmerka, vam bodo pomagale, da: a.
The numbers in the display must line up precisely with the pointer to ensure that you get the correct dose.
Da zagotovite pravilen odmerek, morajo biti številke na zaslonu natančno poravnane s kazalnikom odmerka.
The numbers on the dose display are measured in International Units or IU.
Številke v prikazu odmerka so v mednarodnih enotah ali i.e.
The numbers on the Dose Feedback Window are measured in International Units or IUs.
Številke v oknu za prikaz odmerka so v mednarodnih enotah ali i.e..
The nurse educational guide, including the following key elements:
Vodnik za medicinske sestre, ki vsebuje naslednje ključne točke:
The Nurse Information Pack should contain the following key elements:
Izobraževalno gradivo za medicinske sestre mora vključevati naslednje glavne vsebine:
The NutropinAq cartridge may be used for up to 28 days.
Vložek zdravila NutropinAq smete uporabljati največ 28 dni.
The OATP1B1 inhibition could result in increased exposure of medicinal products such as statins (atorvastatin, fluvastatin, pitavastatin, and lovastatin), repaglinide, bosentan, valsartan, olmesartan, and glyburide.
Zaviranje OATP1B1 lahko povzroči povečano izpostavljenost zdravilom, kot so statini (atorvastatin, fluvastatin, pitavastatin in lovastatin), repaglinid, bosentan, valsartan, olmesartan in gliburid.
The objective is to expose and treat all areas of HGD and the entire length of BO.
Cilj je osvetliti in zdraviti vsa področja HGD ter celotno dolžino BP.
The objective of the first stage was to establish the rituximab subcutaneous dose that resulted in comparable MabThera subcutaneous formulation serum Ctrough levels compared with MabThera intravenous formulation, when given as part of induction treatment every 3 weeks (see section 5.2)..
Cilj prve stopnje je bil določiti podkožni odmerek rituksimaba, ki med uporabo podkožne oblike zdravila MabThera v serumu doseže podobno najmanjšo koncentracijo pred naslednjim odmerkom (Ctrough), kot je dosežena z intravensko obliko zdravila MabThera, če je zdravilo uporabljeno v okviru indukcijskega zdravljenja enkrat na 3 tedne (glejte poglavje 5.2).
The objective of the Part 2 was to establish the non-inferiority in observed Ctrough levels between the confirmed MabThera subcutaneous dose and the reference MabThera intravenous dose.
Cilj 2. dela preskušanja je bil potrditi neinferiornost najmanjše koncentracije pred naslednjim odmerkom (Ctrough), dosežene z določenim odmerkom podkožne oblike zdravila MabThera, v primerjavi z referenčnim odmerkom intravenske oblike zdravila MabThera.
The objective of the RE-MEDY study was to compare the safety and efficacy of oral dabigatran etexilate (150 mg bid) to warfarin (target INR 2.0-3.0) for the long-term treatment and prevention of recurrent, symptomatic DVT and/or PE.
Cilj študije RE-MEDY je bil primerjati varnost in učinkovitost peroralnega dabigatran eteksilata (po 150 mg dvakrat na dan) z varnostjo in učinkovitostjo varfarina (ciljni INR 2,0 do 3,0) pri dolgotrajnem zdravljenju in preprečevanju ponovitev simptomatične GVT in/ali PE.
The objective of the RE-SONATE study was to evaluate superiority of dabigatran etexilate versus placebo for the prevention of recurrent symptomatic DVT and/or PE in patients who had already completed 6 to 18 months of treatment with VKA.
Cilj študije RE-SONATE je bil oceniti superiornost dabigatran eteksilata v primerjavi s placebom pri preprečevanju ponovitve simptomatične GVT in/ali PE pri bolnikih, ki so že končali 6- do
The objective of this double-blind, randomised, placebo controlled trial was to determine whether inhaled nitric oxide would reduce the occurrence of death and/or initiation of extracorporeal membrane oxygenation (ECMO).
Namen tega dvojno slepega, randomiziranega, s placebom nadzorovanega preizkusa je bil določiti, ali vdihani dušikov oksid zniža smrtnost in/ali potrebo po zdravljenju z zunajtelesno membransko oksigenacijo (ECMO – »extracorporeal membrane oxygenation«).